Get the Stockscreener App
5.54
1.60%
-0.09
After Hours:
5.81
0.27
+4.87%
Fennec Pharmaceuticals Inc stock is traded at $5.54, with a volume of 34,107.
It is down -1.60% in the last 24 hours and down -8.73% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$5.63
Open:
$5.7
24h Volume:
34,107
Relative Volume:
0.30
Market Cap:
$151.97M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-9.082
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
-6.26%
1M Performance:
-8.73%
6M Performance:
-16.69%
1Y Performance:
-46.21%
1-Day Range:
$5.47
$5.70
1-Week Range:
$5.47
$5.97
52-Week Range:
$3.96
$11.49
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
5.54 | 151.97M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Sees Large Decrease in Short Interest - MarketBeat
Learn to Evaluate (FENC) using the Charts - Stock Traders Daily
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$87,552.00 in Stock - MarketBeat
Barclays PLC Grows Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock - MarketBeat
Fennec Pharmaceuticals director Raykov Rosty sells $60,800 in shares By Investing.com - Investing.com Australia
Fennec Pharmaceuticals director Raykov Rosty sells $60,800 in shares - Investing.com
Franklin Resources Inc. Has $74,000 Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
State Street Corp Has $1.64 Million Stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (TSE:FRX) Shares Pass Above 50 Day Moving AverageShould You Sell? - MarketBeat
Stocks In Play: Fennec Pharmaceuticals Inc. - Barchart
(FENC) Trading Advice - Stock Traders Daily
Wedbush Raises Earnings Estimates for Fennec Pharmaceuticals - Defense World
Q4 EPS Estimate for Fennec Pharmaceuticals Raised by Analyst - MarketBeat
Wedbush Issues Optimistic Outlook for TSE:FRX Earnings - Defense World
Equities Analysts Issue Forecasts for TSE:FRX Q3 Earnings - MarketBeat
Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - Marketscreener.com
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Acquires C$96,840.00 in Stock - MarketBeat
Fennec Pharmaceuticals’ (FENC) Outperform Rating Reiterated at Wedbush - Defense World
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Long Term Trading Analysis for (FENC) - Stock Traders Daily
Fennec Pharmaceuticals (NASDAQ:FENC) Receives Outperform Rating from Wedbush - MarketBeat
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - The Manila Times
Fennec's PEDMARQSI® Breakthrough: First NHS Treatment for Child Cancer-Related Hearing Loss - StockTitan
HC Wainwright Issues Negative Forecast for TSE:FRX Earnings - Defense World
What is HC Wainwright’s Forecast for FENC FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for TSE:FRX Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for FENC FY2024 Earnings? - MarketBeat
Fennec Pharmaceuticals partially repays its outstanding convertible debt facility - MSN
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management - The Manila Times
Verition Fund Management LLC Sells 23,113 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals' (FENC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Sold by BNP Paribas Financial Markets - Defense World
Stocks In Play: Fennec Pharmaceuticals Inc. By Baystreet.ca - Investing.com Canada
Fennec Pharmaceuticals (TSE:FRX) Trading Down 0.3% – Time to Sell? - Defense World
Fennec Pharmaceuticals (TSE:FRX) Stock Price Down 0.3%Time to Sell? - MarketBeat
Fennec Pharmaceuticals Inc (FRX-T) QuotePress Release - The Globe and Mail
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - The Manila Times
Fennec Pharmaceuticals to Present at H.C. Wainwright Fireside Chat Series - StockTitan
Where are the Opportunities in (FENC) - Stock Traders Daily
Fennec Pharmaceuticals director Raykov Rosty sells shares worth $4,807 - Investing.com
Fennec Pharmaceuticals director Raykov Rosty sells shares worth $4,807 By Investing.com - Investing.com Nigeria
Insider Sell: Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus.com
Fennec Pharmaceuticals director sells $10,022 in stock By Investing.com - Investing.com UK
Fennec Pharmaceuticals director sells $39,351 in shares By Investing.com - Investing.com Canada
Fennec Pharmaceuticals director sells $39,351 in shares - Investing.com India
A Data-Based Look At Fennec Pharmaceuticals Inc (FENC) - Stocks Register
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):